Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anti-HBV specific beta-L-2'-deoxynucleosides.

M L Bryant1, E G Bridges, L Placidi

  • 1Novirio Pharmaceuticals, Inc., 125 Cambridge Park Dr., Cambridge, Massachussetts 02476, USA. bryant.martin@novirio.com

Nucleosides, Nucleotides & Nucleic Acids
|September 21, 2001
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Letter to the Editor regarding the article "Metabolic dysfunction-associated steatotic liver disease and dietary intake characteristics in children and adolescents: A cross-sectional study".

Revista de gastroenterologia de Mexico (English)·2026
Same author

Peripheral autonomic dysregulation in response to standing: a new form associated with cardiovascular disease, mobility reduction, and cognitive alterations.

European heart journal·2026
Same author

The effect of surgical complications on trauma and orthopaedic trainees.

Annals of the Royal College of Surgeons of England·2026
Same author

Bisphosphonate drug holidays in osteoporosis according to fracture risk profile.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2024
Same author

COVID-19 mRNA vaccination and myocarditis/pericarditis in the setting of active surveillance at a military treatment facility.

BMJ military health·2023
Same author

Quality analysis and categorisation of public space.

Heliyon·2023

New L-nucleosides show promise for treating chronic hepatitis B virus (HBV) infection. These compounds specifically inhibit HBV replication without affecting human DNA polymerases or mitochondria.

Area of Science:

  • Virology
  • Medicinal Chemistry
  • Hepatology

Background:

  • Chronic hepatitis B virus (HBV) infection remains a significant global health concern.
  • Current therapies have limitations, necessitating the development of novel antiviral agents.
  • Unnatural nucleosides represent a promising class of antiviral compounds.

Purpose of the Study:

  • To discover and characterize novel L-nucleoside analogs with specific anti-HBV activity.
  • To investigate the structure-activity relationship of these compounds.
  • To evaluate their safety and efficacy in preclinical models.

Main Methods:

  • Synthesis of a series of simple unnatural L-nucleosides.
  • In vitro antiviral activity assays against HBV.

Related Experiment Videos

  • Assessment of selectivity against hepadnaviruses.
  • Evaluation of effects on human DNA polymerases and mitochondrial function.
  • In vivo studies in a woodchuck model of chronic HBV infection.

    • Main Results:

    • A unique series of L-nucleosides specifically inhibit HBV replication.
    • A 3'-hydroxyl group on the beta-L-2'-deoxyribose sugar is crucial for hepadnavirus specificity.
    • Modifications in the base or replacement of the 3'-OH group alter antiviral spectrum and potency.
    • Compounds demonstrated no significant impact on human DNA polymerases or mitochondrial function.
    • Significant reduction (up to 8 logs) in plasma viremia observed in a woodchuck HBV model.

    Conclusions:

    • Novel L-nucleosides with a specific 3'-OH moiety are potent and selective inhibitors of HBV replication.
    • These compounds exhibit a favorable safety profile, sparing human DNA polymerases and mitochondria.
    • Preclinical data suggest these investigational drugs hold potential as new therapeutic options for chronic HBV infection.